why choose us

First received: August 31, 2023

Clinical Trial: Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

Study Status: Completed

Recruit Status: RECRUITING

Condition: Allogeneic Hematopoietic Stem Cell Transplantation

Study Type: INTERVENTIONAL


Official Title: Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (ADAPT)

Brief Summary: This is a prospective, single-arm, phase II study.Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on patient- and disease-related risk.

Read more